Moderna

Moderna Therapeutics is a biotechnology company that develops messenger RNA therapeutics. Every cell in the body uses mRNA to provide real-time instructions to make the proteins necessary to drive all aspects of biology, including in human health and disease. It provides in vivo drug modality that produces human proteins or antibodies inside patient cells.

Moderna Therapeutics also develops various patent applications with various claims ranging from novel nucleotide chemistries to specific drug compositions. It focuses on disease areas, such as inherited genetic disorders, hemophilia, and blood factors, and oncology.

Moderna Therapeutics in 2010 and is headquartered in Cambridge in Massachusetts. It has strategic option agreements with AstraZeneca and Alexion Pharmaceuticals and strategic collaborations with Karolinska Institutet, Institut Pasteur, Karolinska University Hospital, and Merck.

Moderna, established in 2010 and headquartered in United States, North America., specializes in Early Stage Venture investments across Biotechnology, Health Care, Therapeutics, Oncology, Hedge Funds, Financial Services, FinTech, Crowdfunding, Asset Management, Real Estate Investment. The organization boasts a portfolio of 6 investments, with an average round size of $75.3M and 3 successful exits. Their recent investments include Onkaido Therapeutics, Leightal Capital Management, BlackRock, Bridgewater Associates, J.P. Morgan Asset Management. The highest investment round they participated in was $49.8B. Among their most notable exits are Onkaido Therapeutics and Leightal Capital Management. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.